AMGN

Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma

[PR Newswire] – THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ — Amgen (AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laher moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboardSee who Amgen is […]

Data From Phase 3 Pivotal Studies Show Amgen’s Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins

[PR Newswire] – THOUSAND OAKS, Calif., March 30, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced new detailed data from two Phase 3 pivotal studies that showed treatment with its novel investigational cholesterol-lowering … moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboardSee who Amgen is hiring next, click here to view […]

New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen’s Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol

[PR Newswire] – THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering … moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboardSee who Amgen is hiring next, click here to view […]

Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology’s 63rd Annual Scientific Session

[PR Newswire] – THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ — Amgen (AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody th moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboardSee who Amgen is hiring next, […]